Index S&P 500
P/E 35.78
EPS (ttm) 3.17
Insider Own 0.66%
Shs Outstand 1.73B
Perf Week -0.57%
Market Cap 197.24B
Forward P/E 22.04
EPS next Y 5.14
Insider Trans -1.50%
Shs Float 1.73B
Perf Month -0.44%
Income 5.54B
PEG 4.34
EPS next Q 1.20
Inst Own 77.09%
Short Float 0.77%
Perf Quarter 11.53%
Sales 40.73B
P/S 4.84
EPS this Y 4.99%
Inst Trans 0.92%
Short Ratio 2.24
Perf Half Y 2.57%
Book/sh 22.60
P/B 5.02
EPS next Y 10.35%
ROA 7.56%
Short Interest 13.36M
Perf Year 17.84%
Cash/sh 4.15
P/C 27.32
EPS next 5Y 8.24%
ROE 14.47%
52W Range 89.67 - 121.64
Perf YTD 2.99%
Dividend Est. 2.23 (1.96%)
P/FCF 34.88
EPS past 5Y 19.65%
ROI 10.55%
52W High -6.81%
Beta 0.72
Dividend TTM 2.16 (1.91%)
Quick Ratio 1.18
Sales past 5Y 6.10%
Gross Margin 50.63%
52W Low 26.41%
ATR (14) 1.69
Dividend Ex-Date Oct 15, 2024
Current Ratio 1.68
EPS Y/Y TTM 7.89%
Oper. Margin 16.24%
RSI (14) 49.90
Volatility 1.39% 1.47%
Employees 114000
Debt/Eq 0.38
Sales Y/Y TTM 1.24%
Profit Margin 13.59%
Recom 1.78
Target Price 126.05
Option/Short Yes / Yes
LT Debt/Eq 0.33
EPS Q/Q -5.38%
Payout 63.81%
Rel Volume 1.14
Prev Close 112.64
Sales Surprise 0.08%
EPS Surprise 3.17%
Sales Q/Q 4.00%
Earnings Oct 16 BMO
Avg Volume 5.96M
Price 113.36
SMA20 -1.16%
SMA50 1.02%
SMA200 2.97%
Trades
Volume 6,806,171
Change 0.64%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-19-24 Initiated
Piper Sandler
Overweight
$131
Jul-30-24 Downgrade
Edward Jones
Buy → Hold
May-30-24 Initiated
Goldman
Buy
$121
Jul-21-23 Upgrade
Wolfe Research
Underperform → Peer Perform
May-30-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$112
Apr-20-23 Reiterated
Wolfe Research
Underperform
$107 → $103
Apr-20-23 Reiterated
UBS
Buy
$117 → $130
Apr-20-23 Reiterated
Raymond James
Outperform
$116 → $123
Apr-20-23 Reiterated
JP Morgan
Overweight
$118 → $122
Apr-20-23 Reiterated
Bernstein
Outperform
$132 → $133
Apr-20-23 Reiterated
Barclays
Overweight
$125 → $127
Mar-29-23 Initiated
UBS
Buy
$117
Oct-26-22 Initiated
Mizuho
Neutral
$105
Oct-18-22 Initiated
Barclays
Overweight
$118
Oct-12-22 Initiated
Jefferies
Hold
$110
Jul-06-22 Initiated
Wolfe Research
Underperform
$95
Mar-02-22 Resumed
BofA Securities
Buy
$140
Jan-27-22 Reiterated
UBS
Buy
$138 → $142
Jan-27-22 Reiterated
Raymond James
Outperform
$150 → $143
Jan-27-22 Reiterated
Morgan Stanley
Overweight
$157 → $151
Show Previous Ratings
Oct-07-24 11:05AM
Oct-05-24 09:07AM
04:45AM
Oct-02-24 06:00PM
08:35AM
08:00AM
Loading…
08:00AM
04:11AM
Oct-01-24 12:10PM
Sep-30-24 04:49AM
Sep-28-24 01:21PM
05:00AM
Sep-27-24 09:30AM
09:00AM
Sep-26-24 06:00PM
02:00PM
09:00AM
Loading…
Sep-25-24 09:00AM
06:35AM
Sep-20-24 05:50PM
Sep-19-24 12:59PM
09:01AM
04:49AM
04:44AM
04:39AM
04:35AM
04:30AM
04:07AM
04:03AM
03:59AM
03:55AM
03:46AM
08:00AM
Loading…
Sep-18-24 08:00AM
Sep-16-24 06:58PM
06:00PM
09:00AM
05:12AM
Sep-13-24 09:00AM
Sep-11-24 06:59AM
Sep-10-24 05:50PM
Sep-05-24 04:08PM
(Investor's Business Daily)
02:45PM
09:30AM
09:29AM
(Investor's Business Daily)
09:00AM
(Investor's Business Daily)
09:00AM
09:00AM
Sep-04-24 09:00AM
08:00AM
Sep-03-24 11:32PM
05:50PM
Aug-30-24 06:45AM
Aug-29-24 03:26PM
Aug-28-24 05:50PM
Aug-27-24 01:13PM
09:00AM
Aug-25-24 06:30PM
Aug-24-24 03:22PM
Aug-23-24 09:12AM
Aug-22-24 05:50PM
Aug-21-24 01:54PM
09:00AM
08:00AM
Aug-20-24 09:30AM
Aug-17-24 09:10AM
Aug-16-24 08:50PM
Aug-15-24 01:44PM
Aug-14-24 08:00AM
Aug-13-24 07:03PM
07:03PM
02:45PM
03:32AM
Aug-12-24 08:29PM
Aug-11-24 07:28AM
Aug-09-24 09:00AM
Aug-08-24 09:00AM
Aug-07-24 04:57PM
01:45PM
09:00AM
08:00AM
08:00AM
05:10AM
Aug-06-24 04:26PM
04:23PM
09:00AM
Aug-03-24 06:45AM
Aug-02-24 09:30AM
08:00AM
(Investor's Business Daily)
05:17AM
Jul-31-24 11:08AM
Jul-30-24 10:49AM
09:30AM
08:54AM
08:18AM
Jul-29-24 04:32PM
04:16PM
(The Wall Street Journal)
03:47PM
03:23PM
02:37PM
02:06PM
12:29PM
10:46AM
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ford Robert B CHAIRMAN AND CEO Sep 12 '24 Option Exercise 47.19 141,679 6,685,975 361,738 Sep 13 05:24 PM Ford Robert B CHAIRMAN AND CEO Sep 12 '24 Sale 116.41 141,679 16,493,218 220,059 Sep 13 05:24 PM Robert B. Ford Officer Sep 12 '24 Proposed Sale 116.41 141,679 16,492,852 Sep 12 06:20 PM MCCOY JOHN A. JR. VICE PRESIDENT Sep 04 '24 Sale 114.83 27 3,100 18,681 Sep 04 07:52 PM Funck, Jr. Robert E. Officer Sep 04 '24 Proposed Sale 115.00 30,000 3,450,000 Sep 04 04:04 PM Funck, Jr. Robert E. EXECUTIVE VICE PRESIDENT May 10 '24 Option Exercise 47.00 10,097 474,559 221,438 May 14 05:35 PM Funck, Jr. Robert E. EXECUTIVE VICE PRESIDENT May 10 '24 Sale 104.57 10,097 1,055,819 211,341 May 14 05:35 PM Earnhardt Lisa D EXECUTIVE VICE PRESIDENT May 07 '24 Sale 106.25 22,852 2,428,119 61,462 May 08 05:00 PM Salvadori Daniel Gesua Sive EXECUTIVE VICE PRESIDENT Mar 01 '24 Sale 118.50 963 114,116 125,697 Mar 04 07:18 PM Morrone Louis H. EXECUTIVE VICE PRESIDENT Mar 01 '24 Sale 118.50 801 94,918 62,968 Mar 04 07:14 PM Moreland Mary K EXECUTIVE VICE PRESIDENT Mar 01 '24 Sale 118.50 676 80,106 91,260 Mar 04 07:09 PM MCCOY JOHN A. JR. VICE PRESIDENT Mar 01 '24 Sale 118.50 472 55,932 18,760 Mar 04 07:05 PM Earnhardt Lisa D EXECUTIVE VICE PRESIDENT Mar 01 '24 Sale 118.50 694 82,239 84,314 Mar 04 06:50 PM ALLEN HUBERT L EXECUTIVE VICE PRESIDENT Mar 01 '24 Sale 118.50 853 101,080 184,806 Mar 04 06:39 PM Wainer Andrea F EXECUTIVE VICE PRESIDENT Feb 23 '24 Option Exercise 59.94 12,500 749,250 91,204 Feb 27 06:13 PM Wainer Andrea F EXECUTIVE VICE PRESIDENT Feb 23 '24 Sale 120.00 12,500 1,500,000 78,704 Feb 27 06:13 PM Wainer Andrea F EXECUTIVE VICE PRESIDENT Jan 29 '24 Option Exercise 50.80 42,500 2,158,950 90,027 Jan 31 05:30 PM Wainer Andrea F EXECUTIVE VICE PRESIDENT Jan 29 '24 Sale 112.50 42,500 4,781,250 65,027 Jan 31 05:30 PM Wainer Andrea F EXECUTIVE VICE PRESIDENT Dec 14 '23 Option Exercise 44.40 15,000 666,000 80,027 Dec 18 05:36 PM Wainer Andrea F EXECUTIVE VICE PRESIDENT Dec 14 '23 Sale 108.00 15,000 1,620,000 65,027 Dec 18 05:36 PM STARKS DANIEL J Director Oct 26 '23 Sale 94.05 50,000 4,702,526 6,725,316 Oct 30 04:58 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite